Drug Discovery


Drug Discovery Market Research Reports Analysis and Trends

Publication Single User License (PDF) Price
The Generic Drugs Market: 2015 – 2030 - Opportunities, Challenges, Strategies & Forecasts

The Generic Drugs Market: 2015 – 2030 - Opportunities, Challenges, Strategies & Forecasts

Date Published: Feb 17 2015
A generic drug is a pharmaceutical product, usually intended to be interchangeable with an innovator product, that is manufactured without a license from the innovator company and marketed after the expiry date of the patent or other exclusive rights.
 
Already prevalent in the U.S., Europe and much of the developing world, generic drugs are now finding their way into previously untapped markets such as Japan, largely driven by regulatory efforts to reduce healthcare costs.
$2,500.00
Polycythemia Vera-Global API Manufacturers, Marketed and Phase III Drugs Landscape, 2015

Polycythemia Vera-Global API Manufacturers, Marketed and Phase III Drugs Landscape, 2015

Date Published: Feb 5 2015

“Polycythemia Vera-Global API Manufacturers, Marketed and Phase III Drugs Landscape, 2015”, Report provides comprehensive insights about phase III pipeline drugs and marketed drugs across the Polycythemia Vera. A key objective of DelveInsight’s report is to establish the understanding for API Manufacturers for marketed and Phase III Pipeline drugs across the different countries and regions for the drugs falling under Polycythemia Vera. The Report gives insights into patents providing thepatent protection data and marketing exclusivity of all the drugs across the Polycythemia Vera.

$2,000.00
Chlamydia Infections-Global API Manufacturers, Marketed and Phase III Drugs Landscape, 2015

Chlamydia Infections-Global API Manufacturers, Marketed and Phase III Drugs Landscape, 2015

Date Published: Feb 5 2015

“Chlamydia Infections-Global API Manufacturers, Marketed and Phase III Drugs Landscape, 2015”, Report provides comprehensive insights about phase III pipeline drugs and marketed drugs across the Chlamydia Infections. A key objective of DelveInsight’s report is to establish the understanding for API Manufacturers for marketed and Phase III Pipeline drugs across the different countries and regions for the drugs falling under Chlamydia Infections.

$2,000.00
Escherichia Coli Infections-Global API Manufacturers, Marketed and Phase III Drugs Landscape, 2015

Escherichia Coli Infections-Global API Manufacturers, Marketed and Phase III Drugs Landscape, 2015

Date Published: Feb 5 2015

“Escherichia Coli Infections-Global API Manufacturers, Marketed and Phase III Drugs Landscape, 2015”, Report provides comprehensive insights about phase III pipeline drugs and marketed drugs across the Escherichia Coli Infections. A key objective of DelveInsight’s report is to establish the understanding for API Manufacturers for marketed and Phase III Pipeline drugs across the different countries and regions for the drugs falling under Escherichia Coli Infections.

$2,000.00
Idiopathic (Essential) Hypertension-Global API Manufacturers, Marketed and Phase III Drugs Landscape, 2015

Idiopathic (Essential) Hypertension-Global API Manufacturers, Marketed and Phase III Drugs Landscape, 2015

Date Published: Feb 5 2015

“Idiopathic (Essential) Hypertension-Global API Manufacturers, Marketed and Phase III Drugs Landscape, 2015”, Report provides comprehensive insights about phase III pipeline drugs and marketed drugs across the Idiopathic (Essential) Hypertension. A key objective of DelveInsight’s report is to establish the understanding for API Manufacturers for marketed and Phase III Pipeline drugs across the different countries and regions for the drugs falling under Idiopathic (Essential) Hypertension.

$2,000.00
Thromboembolism-Global API Manufacturers, Marketed and Phase III Drugs Landscape, 2015

Thromboembolism-Global API Manufacturers, Marketed and Phase III Drugs Landscape, 2015

Date Published: Feb 5 2015

“Thromboembolism-Global API Manufacturers, Marketed and Phase III Drugs Landscape, 2015”, Report provides comprehensive insights about phase III pipeline drugs and marketed drugs across the Thromboembolism. A key objective of DelveInsight’s report is to establish the understanding for API Manufacturers for marketed and Phase III Pipeline drugs across the different countries and regions for the drugs falling under Thromboembolism. The Report gives insights into patents providing thepatent protection data and marketing exclusivity of all the drugs across the Thromboembolism.

$2,000.00
Septic Shock-Global API Manufacturers, Marketed and Phase III Drugs Landscape, 2015

Septic Shock-Global API Manufacturers, Marketed and Phase III Drugs Landscape, 2015

Date Published: Feb 5 2015

“Septic Shock-Global API Manufacturers, Marketed and Phase III Drugs Landscape, 2015”, Report provides comprehensive insights about phase III pipeline drugs and marketed drugs across the Septic Shock. A key objective of DelveInsight’s report is to establish the understanding for API Manufacturers for marketed and Phase III Pipeline drugs across the different countries and regions for the drugs falling under Septic Shock. The Report gives insights into patents providing thepatent protection data and marketing exclusivity of all the drugs across the Septic Shock.

$2,000.00
Diffuse Posterior Uveitis-Global API Manufacturers, Marketed and Phase III Drugs Landscape, 2015

Diffuse Posterior Uveitis-Global API Manufacturers, Marketed and Phase III Drugs Landscape, 2015

Date Published: Feb 5 2015

“Diffuse Posterior Uveitis-Global API Manufacturers, Marketed and Phase III Drugs Landscape, 2015”, Report provides comprehensive insights about phase III pipeline drugs and marketed drugs across the Diffuse Posterior Uveitis. A key objective of DelveInsight’s report is to establish the understanding for API Manufacturers for marketed and Phase III Pipeline drugs across the different countries and regions for the drugs falling under Diffuse Posterior Uveitis.

$2,000.00
Migraine-Global API Manufacturers, Marketed and Phase III Drugs Landscape, 2015

Migraine-Global API Manufacturers, Marketed and Phase III Drugs Landscape, 2015

Date Published: Feb 5 2015

“Migraine-Global API Manufacturers, Marketed and Phase III Drugs Landscape, 2015”, Report provides comprehensive insights about phase III pipeline drugs and marketed drugs across the Migraine. A key objective of DelveInsight’s report is to establish the understanding for API Manufacturers for marketed and Phase III Pipeline drugs across the different countries and regions for the drugs falling under Migraine. The Report gives insights into patents providing thepatent protection data and marketing exclusivity of all the drugs across the Migraine.

$2,000.00
Metastatic Ovarian Cancer-Global API Manufacturers, Marketed and Phase III Drugs Landscape, 2015

Metastatic Ovarian Cancer-Global API Manufacturers, Marketed and Phase III Drugs Landscape, 2015

Date Published: Feb 5 2015

“Metastatic Ovarian Cancer-Global API Manufacturers, Marketed and Phase III Drugs Landscape, 2015”, Report provides comprehensive insights about phase III pipeline drugs and marketed drugs across the Metastatic Ovarian Cancer. A key objective of DelveInsight’s report is to establish the understanding for API Manufacturers for marketed and Phase III Pipeline drugs across the different countries and regions for the drugs falling under Metastatic Ovarian Cancer.

$2,000.00
AIDS - Related Kaposi's Sarcoma-Global API Manufacturers, Marketed and Phase III Drugs Landscape, 2015

AIDS - Related Kaposi's Sarcoma-Global API Manufacturers, Marketed and Phase III Drugs Landscape, 2015

Date Published: Feb 5 2015

“AIDS - Related Kaposi's Sarcoma-Global API Manufacturers, Marketed and Phase III Drugs Landscape, 2015”, Report provides comprehensive insights about phase III pipeline drugs and marketed drugs across the AIDS - Related Kaposi's Sarcoma. A key objective of DelveInsight’s report is to establish the understanding for API Manufacturers for marketed and Phase III Pipeline drugs across the different countries and regions for the drugs falling under AIDS - Related Kaposi's Sarcoma.

$2,000.00
Atrial Fibrillation-Global API Manufacturers, Marketed and Phase III Drugs Landscape, 2015

Atrial Fibrillation-Global API Manufacturers, Marketed and Phase III Drugs Landscape, 2015

Date Published: Feb 5 2015

“Atrial Fibrillation-Global API Manufacturers, Marketed and Phase III Drugs Landscape, 2015”, Report provides comprehensive insights about phase III pipeline drugs and marketed drugs across the Atrial Fibrillation. A key objective of DelveInsight’s report is to establish the understanding for API Manufacturers for marketed and Phase III Pipeline drugs across the different countries and regions for the drugs falling under Atrial Fibrillation. The Report gives insights into patents providing thepatent protection data and marketing exclusivity of all the drugs across the Atrial Fibrillation.

$2,000.00
Xerosis (Dry Skin)-Global API Manufacturers, Marketed and Phase III Drugs Landscape, 2015

Xerosis (Dry Skin)-Global API Manufacturers, Marketed and Phase III Drugs Landscape, 2015

Date Published: Feb 5 2015

“Xerosis (Dry Skin)-Global API Manufacturers, Marketed and Phase III Drugs Landscape, 2015”, Report provides comprehensive insights about phase III pipeline drugs and marketed drugs across the Xerosis (Dry Skin). A key objective of DelveInsight’s report is to establish the understanding for API Manufacturers for marketed and Phase III Pipeline drugs across the different countries and regions for the drugs falling under Xerosis (Dry Skin). The Report gives insights into patents providing thepatent protection data and marketing exclusivity of all the drugs across the Xerosis (Dry Skin).

$2,000.00
Glioma-Global API Manufacturers, Marketed and Phase III Drugs Landscape, 2015

Glioma-Global API Manufacturers, Marketed and Phase III Drugs Landscape, 2015

Date Published: Feb 5 2015

“Glioma-Global API Manufacturers, Marketed and Phase III Drugs Landscape, 2015”, Report provides comprehensive insights about phase III pipeline drugs and marketed drugs across the Glioma. A key objective of DelveInsight’s report is to establish the understanding for API Manufacturers for marketed and Phase III Pipeline drugs across the different countries and regions for the drugs falling under Glioma. The Report gives insights into patents providing thepatent protection data and marketing exclusivity of all the drugs across the Glioma.

$2,000.00
Pneumonia-Global API Manufacturers, Marketed and Phase III Drugs Landscape, 2015

Pneumonia-Global API Manufacturers, Marketed and Phase III Drugs Landscape, 2015

Date Published: Feb 5 2015

“Pneumonia-Global API Manufacturers, Marketed and Phase III Drugs Landscape, 2015”, Report provides comprehensive insights about phase III pipeline drugs and marketed drugs across the Pneumonia. A key objective of DelveInsight’s report is to establish the understanding for API Manufacturers for marketed and Phase III Pipeline drugs across the different countries and regions for the drugs falling under Pneumonia. The Report gives insights into patents providing thepatent protection data and marketing exclusivity of all the drugs across the Pneumonia.

$2,000.00
Hepatitis C-Global API Manufacturers, Marketed and Phase III Drugs Landscape, 2015

Hepatitis C-Global API Manufacturers, Marketed and Phase III Drugs Landscape, 2015

Date Published: Feb 5 2015

“Hepatitis C-Global API Manufacturers, Marketed and Phase III Drugs Landscape, 2015”, Report provides comprehensive insights about phase III pipeline drugs and marketed drugs across the Hepatitis C. A key objective of DelveInsight’s report is to establish the understanding for API Manufacturers for marketed and Phase III Pipeline drugs across the different countries and regions for the drugs falling under Hepatitis C. The Report gives insights into patents providing thepatent protection data and marketing exclusivity of all the drugs across the Hepatitis C.

$2,000.00
Pyelonephritis-Global API Manufacturers, Marketed and Phase III Drugs Landscape, 2015

Pyelonephritis-Global API Manufacturers, Marketed and Phase III Drugs Landscape, 2015

Date Published: Feb 5 2015

“Pyelonephritis-Global API Manufacturers, Marketed and Phase III Drugs Landscape, 2015”, Report provides comprehensive insights about phase III pipeline drugs and marketed drugs across the Pyelonephritis. A key objective of DelveInsight’s report is to establish the understanding for API Manufacturers for marketed and Phase III Pipeline drugs across the different countries and regions for the drugs falling under Pyelonephritis. The Report gives insights into patents providing thepatent protection data and marketing exclusivity of all the drugs across the Pyelonephritis.

$2,000.00
Pulmonary Fibrosis-Global API Manufacturers, Marketed and Phase III Drugs Landscape, 2015

Pulmonary Fibrosis-Global API Manufacturers, Marketed and Phase III Drugs Landscape, 2015

Date Published: Feb 5 2015

“Pulmonary Fibrosis-Global API Manufacturers, Marketed and Phase III Drugs Landscape, 2015”, Report provides comprehensive insights about phase III pipeline drugs and marketed drugs across the Pulmonary Fibrosis. A key objective of DelveInsight’s report is to establish the understanding for API Manufacturers for marketed and Phase III Pipeline drugs across the different countries and regions for the drugs falling under Pulmonary Fibrosis. The Report gives insights into patents providing thepatent protection data and marketing exclusivity of all the drugs across the Pulmonary Fibrosis.

$2,000.00
Colorectal Cancer-Global API Manufacturers, Marketed and Phase III Drugs Landscape, 2015

Colorectal Cancer-Global API Manufacturers, Marketed and Phase III Drugs Landscape, 2015

Date Published: Feb 5 2015

“Colorectal Cancer-Global API Manufacturers, Marketed and Phase III Drugs Landscape, 2015”, Report provides comprehensive insights about phase III pipeline drugs and marketed drugs across the Colorectal Cancer. A key objective of DelveInsight’s report is to establish the understanding for API Manufacturers for marketed and Phase III Pipeline drugs across the different countries and regions for the drugs falling under Colorectal Cancer. The Report gives insights into patents providing thepatent protection data and marketing exclusivity of all the drugs across the Colorectal Cancer.

$2,000.00
Herpes Labialis (Oral Herpes)-Global API Manufacturers, Marketed and Phase III Drugs Landscape, 2015

Herpes Labialis (Oral Herpes)-Global API Manufacturers, Marketed and Phase III Drugs Landscape, 2015

Date Published: Feb 5 2015

“Herpes Labialis (Oral Herpes)-Global API Manufacturers, Marketed and Phase III Drugs Landscape, 2015”, Report provides comprehensive insights about phase III pipeline drugs and marketed drugs across the Herpes Labialis (Oral Herpes). A key objective of DelveInsight’s report is to establish the understanding for API Manufacturers for marketed and Phase III Pipeline drugs across the different countries and regions for the drugs falling under Herpes Labialis (Oral Herpes).

$2,000.00

Pages

Shopping cart

0 Items $0.00
Not able to find what you are looking for?
Call Us
WHY CHOOSE MARKET RESEARCH REPORTS?
1
Trusted By Leaders
2
Shop With Confidence
3
Customer Centric
4
Personalized Solutions
5
Secure Checkout

User login

Clients Who Trust Us

Orange, Google, Microsoft, Barclays, CassidianIntel, TPG, Elit Net, Cross Business Producers, AcmavolpakP&G, Cisco, Gemalto, General Insurance Corporation of India, Aviva, Cognizant, InoxWindB. Braun, Cobham, fiserv, Harris, Wipro, AonAl Meera, Nomura Research Institute, Tata Consultancy Services, Amara Raja, Hiranandani EnergyMunich Re, Lotte Chemical, National Post, First Data